A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan

Fumihiko Sakai¹, Koichi Hirata², Hisaka Igarashi³, Takao Takeshima⁴, Takeo Nakayama⁵, Hiromi Sano⁶*, Hiroyuki Kondo⁷, Yoshiyuki Shibasaki⁷ and Nobuyuki Koga⁸

Abstract

Background: Migraine is a chronic disease characterized by episodic headache attacks. No recent studies have, however, been conducted on the epidemiology of migraine or the treatment landscape in Japan. This study was conducted as a fact-finding survey using medical claims data and an online survey on migraine and headaches, conducted among members of health insurance associations with the objective of gaining an understanding of migraine prevalence and the treatment status in Japan.

Methods: The study methodology utilized a unique approach of combined data sources. The data sources used in this study are medical claims data and linked online survey data provided by DeSC Healthcare Inc (DeSC). The primary outcomes (from survey responses) were: the overall number and proportion of migraine patients; and the overall prevalence of migraine, stratified by age and sex. The secondary outcomes (from survey responses) were use of medical care; and clinical features/headache symptoms. The analysis population included all individuals who had response data for surveys conducted by DeSC. The online survey data and medical claims data were summarized.

Results: The data population comprised 21,480 individuals. On the basis of the survey results, including probable cases, the overall prevalence of migraine was 3.2%. The highest prevalence of migraine was observed in patients aged 30–39 years. The prevalence of migraine in women was 4.4 times higher than in men. The percentage of migraine patients who had not been seen by a doctor was 81.0%. More than 80% of patients were taking over-the-counter drugs and 6.1% took prescription medicines only. Approximately 52.9% of patients considered that the intensity of pain symptoms was severe. Moreover, the majority of patients (72.9%) considered that the impairment of daily life activities was of moderate or severe degree.

Conclusions: In Japan, the percentage of people with migraine who did not receive medical attention is as high as 80%. Additionally, the majority of patients tend to endure symptoms and continue with everyday activities. With innovative treatment approaches becoming available it is necessary to disseminate information that migraine is not a simple headache but an illness that requires medical treatment and consultation.

*Correspondence: sanoh@otsuka.jp

Medical Affairs, Otsuka Pharmaceutical Co., Ltd, 3-2-27 Otedori, Chuo-ku, Osaka 540-0021, Japan
Full list of author information is available at the end of the article

© The Author(s) 2022, corrected publication 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Migraine is a chronic disease characterized by episodic headache attacks. The headache attacks are described as unilateral and pulsating, of moderate to severe intensity, and lasting 4–72 h [1]. In addition to “headache,” migraine may also be accompanied by symptoms such as nausea and vomiting, photophobia, phonophobia, and osmophobia, as well as visual abnormalities, including aura (jagged geometric patterns of glittering lights that gradually obscure vision, mosaic of parts of vision, etc.), which greatly interfere with daily life [2].

There are nine reports of epidemiological studies of headache disorders in Japan, [3–11], of which six are in adults [4, 7–11]. According to a nationwide telephone survey by Sakai & Igarashi reported in 1997 [3], the prevalence of tension-type headache was 15.6% and that of migraine was 8.4%. The prevalence of migraine by sex was higher in females (12.9% compared to 3.6% in males), with the highest incidence in the 30–40 age group. The results also showed that 74% of people that experienced migraine symptoms reported that their headache attacks interfered with their daily lives, but they were generally able to conduct work and other social activities. The percentage of those who had never been to a medical institution for migraine was 69.4%. In terms of medication status, only 5.4% of patients took prescription medication, and 56.8% used over-the-counter (OTC) analgesics only. Overall, these reports showed that many people with migraine do not seek medical attention; rely on OTC analgesics for headache treatment; and do not take time off from social activities (or endure them) even when headaches interfere with daily life. This situation has been described as Japanese migraine patients “suffering in silence” [12].

In the field of headache medicine, triptans, which are serotonin 1B/1D receptor agonists, were approved in Japan in 2001 for the acute treatment of migraine. Until then, analgesia with non-steroidal anti-inflammatory drugs (NSAIDs) had been the mainstay of migraine treatment, but the introduction of a mechanism-of-action treatment that matched the migraine onset mechanism was expected to improve treatment effectiveness by reducing the number of headache attacks and attack severity. In addition, it was expected that use of triptans would increase the number of people who visited medical institutions rather than enduring headaches. The 2021 Guidelines for the Management of Chronic Headache placed triptans as the first-line treatment for the acute phase of moderate-to-severe migraine headache [1], which was a change in migraine treatment policy. Due to the fact that no actual research studies evaluating triptans have been reported, it is still unclear, however, how the low consultation rate; reliance on OTC analgesics; changes in disruption of daily life, quality of life; and consultation trends have changed due to the use of triptans.

In 2019 monoclonal antibodies drugs targeting the calcitonin gene-related peptide (CGRP) or the CGRP receptor with a novel mechanism of action for migraine were launched in the United States and Europe. CGRP is a neuropeptide that was first reported to be associated with migraine in 1982, and subsequent studies have also shown an association with migraine. In Japan, monoclonal antibodies drugs targeting CGRP or its receptor are approved, or under evaluation in current clinical trials, and are expected to provide further improvement in migraine medication.

Two studies, on the actual condition of migraine were reported in 2019: an analysis of disease burden and treatment patterns in migraine patients using the Adelphi Migraine Disease Identification Program (a survey developed in the UK) [7], and an analysis of drug dosing patterns for migraine medications using the Japan Medical Data Center (JMDC) (medical claims database) database [8]. These reports are based on surveys of migraine patients and the analysis of prescription patterns using claims data. Due to the limits of this approach the current status in Japan, however, is that the actual prevalence of migraine is not clear. Additionally, it is not clear how the migraine sex ratio, migraine severity, migraine impact on daily life, medication status, and consultation trends in the general population, which were reported about 20 years ago [3], have changed since the launch of triptans.

The main purpose of this study was to gain an understanding of the actual prevalence of migraine and the treatment status in Japan. Additionally, the results of this study help clarify the current status of medical consultation and the reasons for discontinuing existing preventive medications.

Methods

Study design and data source

The study was conducted as a fact-finding survey using the unique combination of medical claims data from a health insurance association (HIA) and the linked results of an online survey on migraine and headaches conducted among members of health insurance associations.
contracted by DeSC Healthcare Inc (DeSC)., and indi-

dividuals registered with the health promotion support service

computer application, known as kencom, provided by
DeSC. This combined use of data sources is thought to be
unique and a particular strength of this study design.

Figure 1 provides a description of the study population.
Medical claims data was acquired from the “Health Insur-
ance Association Registered Population”. This association
comprises individuals aged 19–74 years and is managed
by DeSC. Individuals registered in the health insurance
association are offered the opportunity to voluntarily
enroll in a health promotion support service computer
application, known as kencom. In the conduct of this
study individuals registered with kencom were invited
to participate in on-line health surveys. The health sur-
vey was conducted over a one month period of 1st to 30th
November 2020, with a month response period. To avoid
potential bias no mention of migraine was made in the
health survey invitations. The individuals from whom
health surveys were received comprised the survey popu-
lation. The data sources used in this study are, therefore,
medical claims data and online survey data. This data
source is anonymously processed information compris-
ing medical claims and survey data provided by the Soci-
ety-Managed Employment-Based Health Insurance prior
to the start of this study. Survey data was anonymously
processed after data linkage with the medical claims data
based on individual consent. Therefore, the research that
was conducted in this study used only anonymously pro-
cessed information that had already been created.

The HIA database contains individual-level demo-
graphic information (e.g., age, sex) and dated medical
information for inpatient and outpatient service provided
by health care organizations and pharmacies (e.g., start of
treatment, name of procedure, name of prescription and
disease coded in the International Statistical Classifica-
tion of Diseases and Related Health Problems, 10th revi-
sion, name of medical service, cost,). Provided that the
employee did not leave the insurance program (e.g. reti-
ring, changing jobs), it was possible to trace the medical
and treatment history from multiple institutions.

Ethics statement
As this survey used only anonymized data, and because
Otsuka Pharmaceutical Co., Ltd., Clinical Study Sup-
port Inc. (CSS), and the medical experts did not possess
or receive data correspondence sheets, it was impos-
sible to identify any individual. In addition, DeSC does
not have a correspondence table for the data provided
to Otsuka Pharmaceutical Co., Ltd, and it is, therefore,
impossible to identify individuals from this data. There-
fore, no new individual level consent was obtained for
the use of the data in this study. However, the study
protocol was approved by the ethics committee of the

![Diagram](image.png)

**Fig. 1** Description of the study population. *1 Insured: Insured persons and their dependents. *2 Persons in the population that have registered
information and claims information if they have visited medical institution. *3 Survey responses, claims information, and registration information
can be merged with registered ID. *4 Among 21,704 survey respondents, 21,480 people were included in the analysis population. A total of 224
respondents were excluded from the analysis population as their age and gender did not match the claims data
Research Institute of Healthcare Data Science (approval No.: RI2020012). Additionally, this survey was, however, conducted in consideration of the Declaration of Helsinki (revised October 2013) by the World Medical Association and the Ethical Guidelines for Medical Research Involving Human Subjects.

**Study population**

We extracted online survey response data and medical claims data from the database for the past three years including the month in which the survey was conducted from 1 December 2017 to 30 November 2020. The study population included in the study was defined as “all individuals whose response data were available”.

**Outcome measures**

**Primary outcomes**

The primary outcomes (based on the online survey response) were:

1. The overall number and proportion of people with migraine.
2. The overall prevalence of migraine, stratified by age and sex.

The definition of migraine (Additional file 1) was based on the structured survey response, including internal diagnostic criteria, as migraine with and without aura, including probable migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) [13]. Additionally, prevalence of tension-type headache and cluster headache which were also classified according to ICHD-3 were also examined. Individuals not classified in any of these headache types are included in other headache types (Additional file 2).

**Secondary outcomes**

**Use of medical care (based on the online survey response)** The use of medical care was categorized as follows: The number of individuals with migraine who made hospital visits for headache (regularly visited, not regularly visited, not visited) within 6 months before answering the survey, overall and stratified by age and sex; frequency of hospital visits (<once/month, once/month, once/2 months, once/3 months, <once/3 months); reasons for visiting a hospital (unable to tolerate headaches, worried about other brain diseases, increased headache frequency, and OTC drugs no longer effective; and reasons for not visiting a doctor OTC drugs effective, used to having headache, spontaneously resolving after endurance, or pain not sufficiently severe).

**Clinical features and symptoms of headache (based on the online survey response)** Clinical features/symptoms were classified as follows: symptoms of headache (nausea or vomiting, stiff shoulder, and neck pain); site of pain (unilateral, bilateral, frontal, occipital, periorbital, other locations); time of day of headache onset (Upon waking, morning, afternoon, evening, other, no particular time of day); headache triggers (fatigue physical or mental stress, severe weather systems such as typhoons, lack of sleep, turning points of the seasons, sunny or rainy days, work or housework, and menstruation); activities that were refrained from or reduced by headache (Operating a computer or smart phone, drinking alcohol, exercising such as playing sports or walking, going to crowded places, driving a car, housework (excluding grocery shopping, laundry, and cooking), cooking, socializing with friends and playing with children, going grocery shopping, and taking public transportation).

**Medication use (based on the online survey response and medical claims data) and comorbidity (medical claims data)** Medical use was classified as follows: current medication use (OTC and prescription drugs, prescription drugs only (both acute and prophylactic medications), OTC drugs only, and none); number of OTC drug class use (1 or ≥ 2 types); prescription drugs for prophylactic treatments (antidepressants, anti-epileptics, calcium channel blockers, angiotensin-receptor blockers/angiotensin converting enzyme inhibitors, Beta blockers, and others); prescription drugs for acute treatments (acetaminophen, NSAIDs, triptans, ergotamine, and antiemetic drugs); and comorbidity (hypertension, cardiovascular disease, cerebrovascular disease, gastrointestinal disorder, psychiatric and psychosomatic disorder, depression, epilepsy, asthma, allergy, and autoimmune disorder).

**Activity impairment, MS-QOL, and Work Productivity and Activity Impairment WPAI score (based on the online survey response)** Activity impairment was classified as follows: severity of migraine when taking medicines or not taking medicines (severe, moderate, mild); impairment in daily activities (severe, moderate, mild); Migraine-Specific Quality of Life (MS-QOL) estimated using the MSQ version 2.1, which is a 14-item questionnaire measuring the impact of migraine across 3 domains during the past 4 weeks: role function-restrictive (RR) that measures functional limitations on daily, work, and social activities (7 items); role function-preventive (RP) that measures functional prevention on daily, work, and social activities (4 items); and emotional function (EF) that measures the impact on emotion (3 items) [14–16]. The source data responses were scaled to range from 0 to 100;
the higher score indicating better quality of life. Work Productivity Activity Impairment (WPAI) scores were estimated using the WPAI Questionnaire-General Health for the last 7 days before questionnaire response as follows: 1) percentage of work time missed in the last week due to health conditions (absenteeism); 2) percentage of impairment while working due to health conditions (presenteeism); 3) percentage of overall work impairment due to health conditions; and 4) percentage of activity impairment due to health conditions [17].

Sex and age distribution of each headache type and the prevalence of headache type after weighting by age and sex (Additional file 3) The proportion of each headache type in the analysis population was used to estimate the number of cases of each headache type among kencom registrants and health insurance members by sex and age categories. The number of cases of each headache type among kencom registrants and health insurance members by sex and age category was summed for each headache population, from which the prevalence rate was calculated.

Statistical analysis
The analysis population included all individuals who had response data for the surveys conducted by DeSC. Demographic and clinical characteristics were descriptively summarized for overall individuals with migraine. For continuous variables, the mean ± standard deviation and median (minimum, maximum) were presented. For categorical variables, the number and percentage were presented. Post-hoc analysis of other headaches was conducted using criteria from the ID-Migraine [18] and the 4-item simple migraine screener [19]. Additionally, a sensitivity analysis of the health outcomes of kencom users was conducted, to evaluate whether kencom users showed greater health conscious behaviors than other patients. All statistical analyses were performed in SAS Release 9.4 (SAS Institute, Inc., NC, USA).

Results
Prevalence
The study flow is displayed in Fig. 2. A total of 603,337 individuals were registered in the health insurance association. Medical claims health data were available from individuals in this population that had visited a medical institution during the study period. From the health insurance association registered population, a total of 153,545 individuals had chosen to register in the kencom health promotion support service. Amongst individuals registered with kencom, 21,480 individuals completed the online surveys and comprised the study population.

On the basis of the online survey results, that included probable cases, the overall prevalence of migraine was 3.2% (691/21,480) (Fig. 3). After weighting the data by age and sex among kencom registrants (Additional file 3) the prevalence of migraine was 3.5%. Whereas, after weighting the data by sex and age among health insurance association members (Additional file 3), the prevalence of migraine was 4.2%. From medical claims data (Table 1) the prevalence of migraine was 1.0% (208/21,480).

Of those individuals classified as having migraine in the survey, 8.8% (61/691) had a migraine diagnosis in their medical claims data (Table 1). Among this population of people with migraine that were identified in both the survey and in the medical claims data, the prevalence of chronic migraine was 2.7% (19/691) (Fig. 2).

Prevalence of other headache types are shown in Fig. 3. Among individuals that had "other headache types", 261 patients had at least two matches for ID-Migraine and 286 patients had at least two matches in the 4-item-simple migraine screener (Fig. 2).

By age, among people that experienced migraine, the highest proportion was observed in 37.9% (262/691) of patients aged 40–49 years; followed by 26.6% (184/691) of patients aged 30–39 years; and 25.3% (175/691) of patients aged 50–59 years (Table 1). Additionally Fig. 4 shows the prevalence of migraine stratified by age and sex, with the number of same age and sex category used as the denominator. After stratifying by age and sex, the prevalence of migraine in men and women aged 30–39 years was 4.4% and 9.8% respectively, showing that individuals in the range 30–39 are most likely to experience migraine headache.

Regarding sex, the prevalence of migraine in women was 4.4 times higher than in men (men: women = 1.7%: 7.4%; Fig. 4). After weighting the data by sex and age among kencom registrants (Additional file 3) the ratio of women experiencing a migraine episode was 3.75 times that of men (men: women = 2.0%: 7.5%; Additional File 3). Whereas after weighting the data by sex and age among health insurance association members (Additional file 3), the ratio of women experiencing a migraine episode was 3.1 of that in men (men: women = 2.2%: 6.9%).

Use of medical care
The percentage of people with migraine who had not visited a doctor was 81.0% (560/691) (Table 2). For people that did attend a hospital, the percentage of individuals that visited a clinic was 3.1 times that of general hospitals. The specialties of the clinics in descending order were internal medicine, neurosurgery, and neurology (including multiple responses from online survey for hospitals/clinics). For the characteristics of people with migraine by job category please refer to Additional file 4.
The majority of people with migraine visited a doctor less than once a month (Table 3). The reasons for seeing a doctor were as follows: because they were unable to tolerate headaches (15.3%, 106/691); because they were worried about other brain diseases (9.4%, 65/691); because of increased headache frequency (8.0%, 55/691);
and because OTC drugs were no longer effective (6.9%, 48/691) (Table 3).

A total of 2.6% of people with migraine (18/691) stopped attending a hospital after one visit (Table 3) and the reason provided was because they were relieved not to have a brain disease that threatened life.

Among people with migraine (Table 3) the reasons for not seeing a doctor Additional file 5) were as follows: because OTC drugs were effective (37.6%, 260/691); because they were used to having a headache (22.4%, 155/691); because the symptoms would spontaneously resolve after endurance (20.7%, 143/691); and pain not sufficiently severe (16.5%, 114/691).

Clinical features and symptoms
The reported symptoms of headaches included nausea and vomiting (49.9%, 345/691), stiff shoulders (35.9%, 248/691), and neck pain (26.8%, 185/691) (Tables 4 and 5). The most common locations for headaches were unilateral (84.7%, 585/691) and periorbital (36.0%, 249/691).

The most common triggers provided for headache onset (Table 4 and Additional file 6) was, fatigue (47.3%, 327/691); and physical or mental stress (44.4%, 307/691). Other reasons included severe weather systems such as typhoons (41.4%, 286/691); and weather related situations including; turning points in the season (30.1%, 208/691); and sunny or rainy days (27.6%, 191/691). For women with menstruation 52.6% (171/325) selected the reason for headache onset as menstruation-related. The most common problem that migraine brings to daily life is “inability to concentrate on work or study.”

Activities refrained from or reduced by migraine symptoms in men in decreasing order (Table 5), were as follows: operating a computer or smart phone (32.7%, 89/272); drinking alcohol (32.4%, 88/272); and exercising such as playing sports or walking (21.3%, 58/272). Women selected going to crowded places (37.5%, 157/419); operating a computer or smart phone (35.1%, 147/419); drinking alcohol (30.1%, 126/419); housework (excluding grocery shopping, laundry, and cooking) (21.7%, 91/419); and grocery shopping (21.5%, 90/419).

In order to improve daily life, 55.7% of the respondents felt that they would “like the headache to disappear almost completely,” and 29.6% felt that they would “like it to decrease even a little.” As the level of difficulty increased, the percentage of those who felt that “even a small decrease would be enough” decreased, while the percentage of those who felt that “almost all of the headaches should disappear” increased.

Medication use
More than 80% of people with migraine were taking OTC drugs (89.6%, 561/626) (Table 6). Only 6.1% (38/626) of patients took prescription medicines only and 31.8% (199/626) of patients took both OTC and prescription medicines. Regarding OTC drugs, 22.9% (158/691)
| Variables                  | Analysis population (N = 21,480) | Migraine* (N = 691) | Migraine total (N = 691) | Chronic headache (N = 19) | Episodic headache (N = 672) |
|---------------------------|----------------------------------|--------------------|--------------------------|--------------------------|-----------------------------|
|                           | n | %    | n | %    | n | %    | n | %    | n | %    |
| Sex                       |   |      |   |      |   |      |   |      |   |      |
| Male                      | 15,802 | 73.6 | 272 | 39.4 | 5 | 26.3 | 267 | 39.7 |   |      |
| Female                    | 5,678 | 26.4 | 419 | 60.6 | 14 | 73.7 | 405 | 60.3 |   |      |
| Age, Total                | 1,151 | 5.4 | 60 | 8.7 | 1 | 5.3 | 59 | 8.8 |   |      |
| 19–29 years               | 2,944 | 13.7 | 184 | 26.6 | 7 | 36.8 | 177 | 26.3 |   |      |
| 30–39 years               | 6,095 | 28.4 | 262 | 37.9 | 7 | 36.8 | 255 | 37.9 |   |      |
| 40–49 years               | 8,265 | 38.5 | 175 | 25.3 | 4 | 21.1 | 171 | 25.4 |   |      |
| 50–59 years               | 3,025 | 14.1 | 10 | 1.4 | 0 | 0.0 | 10 | 1.5 |   |      |
| ≥ 60 years                | 275 | 1.3 | 4 | 0.6 | 0 | 0.0 | 4 | 0.6 |   |      |
| Male                      | 675 | 3.1 | 19 | 7.0 | 0 | 0.0 | 19 | 7.1 |   |      |
| 19–29 years               | 1,921 | 8.9 | 84 | 30.9 | 3 | 60.0 | 81 | 30.3 |   |      |
| 30–39 years               | 4,035 | 18.8 | 94 | 34.6 | 2 | 40.0 | 92 | 34.5 |   |      |
| 40–49 years               | 6,483 | 30.2 | 71 | 26.1 | 0 | 0.0 | 71 | 26.6 |   |      |
| 50–59 years               | 2,688 | 12.5 | 4 | 1.5 | 0 | 0.0 | 4 | 1.5 |   |      |
| ≥ 60 years                | 476 | 2.2 | 41 | 9.8 | 1 | 7.1 | 40 | 9.9 |   |      |
| Female                    | 1,023 | 4.8 | 100 | 23.9 | 4 | 28.6 | 96 | 23.7 |   |      |
| 19–29 years               | 2,060 | 9.6 | 168 | 40.1 | 5 | 35.7 | 163 | 40.2 |   |      |
| 30–39 years               | 1,782 | 8.3 | 104 | 24.8 | 4 | 28.6 | 100 | 24.7 |   |      |
| 40–49 years               | 337 | 1.6 | 6 | 1.4 | 0 | 0.0 | 6 | 1.5 |   |      |
| ≥ 60 years                | - | - | - | - | - | - | - | - | - | - |
| Years lived with headache | - | - | - | - | - | - | - | - | - | - |
| -5 years                  | - | - | - | - | - | - | - | - | - | - |
| 6—10 years                | - | - | - | - | - | - | - | - | - | - |
| 11—15 years               | - | - | - | - | - | - | - | - | - | - |
| 16—20 years               | - | - | - | - | - | - | - | - | - | - |
| 21—25 years               | - | - | - | - | - | - | - | - | - | - |
| 26—30 years               | - | - | - | - | - | - | - | - | - | - |
| ≥ 31 years                | - | - | - | - | - | - | - | - | - | - |
| Area of residence         | - | - | - | - | - | - | - | - | - | - |
| Hokkaido                  | - | - | 6 | 0.9 | 0 | 0.0 | 6 | 0.9 |   |      |
| Tohoku                    | - | - | 23 | 3.3 | 0 | 0.0 | 23 | 3.4 |   |      |
| Kanto-Koshinetsu          | - | - | 399 | 57.7 | 9 | 47.4 | 390 | 58.0 |   |      |
| Hokuriku                  | - | - | 8 | 1.2 | 0 | 0.0 | 8 | 1.2 |   |      |
| Chubu                     | - | - | 86 | 12.4 | 4 | 21.1 | 82 | 12.2 |   |      |
| Kinki                     | - | - | 121 | 17.5 | 4 | 21.1 | 117 | 17.4 |   |      |
| Chugoku                   | - | - | 10 | 1.4 | 1 | 5.3 | 9 | 1.3 |   |      |
| Shikoku                   | - | - | 10 | 1.4 | 0 | 0.0 | 10 | 1.5 |   |      |
| Kyushu                    | - | - | 28 | 4.1 | 1 | 5.3 | 27 | 4.0 |   |      |
| Job categoryb             | - | - | 231 | 33.4 | 8 | 42.1 | 223 | 33.2 |   |      |
| Administrative positions  | - | - | 186 | 26.9 | 5 | 26.3 | 181 | 26.9 |   |      |
| Professional and technical personnel | - | - | - | - | - | - | - | - | - | - |
| Housewife (husband)       | - | - | 58 | 8.4 | 2 | 10.5 | 56 | 8.3 |   |      |
| Managers                  | - | - | 47 | 6.8 | 0 | 0.0 | 47 | 7.0 |   |      |
| Others                    | - | - | 169 | 24.5 | 4 | 21.1 | 165 | 24.6 |   |      |
Table 1 (continued)

| Variables                                      | Analysis population (N = 21,480) | Migraine (N = 691) | Chronic headache (N = 19) | Episodic headache (N = 672) |
|------------------------------------------------|----------------------------------|--------------------|---------------------------|----------------------------|
|                                                 | n                               | %                  | n                      | %                          | n                      | %                          |
| Annual household income (including tax)         |                                  |                    |                          |                            |                          |
| <$ 1,000,000 JPY (< 9,000 USD)                   | -                                | -                  | 11                       | 1.6                        | 1                       | 5.3                        |
| ≥ $1,000,000 to <$ 5,000,000 JPY (≥ 9,000      | -                                | -                  | 136                      | 19.7                       | 4                       | 21.1                       |
| to <$44,000 USD)                                |                                  |                    |                          |                            |                          |                            |
| ≥ $5,000,000 to < $10,000,000 JPY (≥ 44,000     | -                                | -                  | 360                      | 52.1                       | 10                      | 52.6                       |
| to <$87,000 USD)                                |                                  |                    |                          |                            |                          |                            |
| ≥ $10,000,000 JPY (≥ 87,000 USD)                | -                                | -                  | 119                      | 17.2                       | 2                       | 10.5                       |
| Don’t know                                     | -                                | -                  | 54                       | 7.8                        | 2                       | 10.5                       |
| No reply                                       | -                                | -                  | 11                       | 1.6                        | 0                       | 0.0                        |
|                                 |                                  |                    |                          |                            |                          |                            |
| Aura                                           | -                                | -                  | 230                      | 33.3                       | -                       | -                          |
| With aura                                      | -                                | -                  | 89                       | 38.7                       | -                       | -                          |
| Male                                           | -                                | -                  | 141                      | 61.3                       | -                       | -                          |
| Female                                         | -                                | -                  | 461                      | 66.7                       | -                       | -                          |
| Without aura                                   | -                                | -                  | 183                      | 39.7                       | -                       | -                          |
| Male                                           | -                                | -                  | 278                      | 60.3                       | -                       | -                          |
| Female                                         | -                                | -                  | 54                       | 7.8                        | 2                       | 10.5                       |
| Number of days with a headache in the past      |                                  |                    |                          |                            |                          |
| 3 months                                       | n                               | -                  | 691                      | 100.0                      | 19                      | 100.0                      |
| Mean                                           | -                                | -                  | 11.1                     | 60.5                       | 9.7                      | 60.5                       |
| SD                                             | -                                | -                  | 12.3                     | 14.6                       | 8.9                      | 14.6                       |
| Min                                            | -                                | -                  | 1.0                      | 45.0                       | 1.0                      | 45.0                       |
| Median                                         | -                                | -                  | 7.0                      | 60.0                       | 7.0                      | 60.0                       |
| Max                                            | -                                | -                  | 90.0                     | 90.0                       | 60.0                     |                            |
| Number of days with a headache in the past      |                                  |                    |                          |                            |                          |
| 30 days                                        | n                               | -                  | 691                      | 100.0                      | 19                      | 100.0                      |
| Mean                                           | -                                | -                  | 5                        | 19                         | 4                        |                            |
| SD                                             | -                                | -                  | 5.0                      | 5.1                        | 4.3                      |                            |
| Min                                            | -                                | -                  | 0.0                      | 15.0                       | 0.0                      |                            |
| Median                                         | -                                | -                  | 3.0                      | 20.0                       | 3.0                      |                            |
| Max                                            | -                                | -                  | 30.0                     | 30.0                       | 30.0                     |                            |
| Receipt code for migraine in the past 6 months  | Yes                             | -                  | 61                       | 8.8                        | -                       | -                          |
| Diagnosed with migraine at the medical institution | Yes | - | 167 | 24.2 | 6 | 31.6 | 161 | 24.0 |

Abbreviations: JPY: Japanese yen, USD: United States dollar, SD: Standard deviation, min: Minimum, max: Maximum

a Migraine included individuals classified as probable migraine
b Details are listed in Additional File 1
c USD was estimated based on the exchange rate of 1 JPY = 0.0087 USD on 09 February 2022
d Data were derived from the medical claims database
of people with migraine took more than one type of OTC medication. Acute care prescription medications were prescribed to 34.9% (241/691) of the respondents. Acetaminophen and NSAIDs were prescribed to 29.8% (206/691) of patients; and triptans to 5.9% (41/691) of patients. Prescription drugs for prophylaxis were prescribed to 8.1% (56/691) of patients. These medications included antidepressants (3.3%, 23/691), antiepileptics (1.9%, 13/691), and calcium channel blockers (1.6%, 11/691). Whilst 59 patients were prescribed triptans for "other headaches," as triptans are only used for migraine, it is highly likely that the "other headache" category includes migraine patients.

**Activity impairment, MS-QOL, and WPAI**

Regarding pain intensity (Table 7), approximately 52.9% (365/691) of respondents considered that the intensity of pain symptoms was severe. Moreover, the majority of patients (72.9%) considered that the impairment of daily life activities was of moderate or severe degree.

The mean (SD) MSQ scores for migraine were 71.6 (17.1) for RR, 83.5 (16.0) for RF, and 77.9 (20.1) for EF. The mean (SD) WPAI score was 2.5% (8.9) for absenteeism, and 15.4% (21.8) for presenteeism (Fig. 5).

**Discussion**

This study was conducted using a unique methodology, combing medical claims data and the results of a linked online survey on migraine and headaches, conducted among members of a health insurance association with the objective of gaining an understanding of the prevalence of migraine and the treatment status in Japan. It is the first study to investigate the prevalence of migraine in Japan for more than 20 years [3]. Whilst this is not a traditional population prevalence study, as our study population contained a large number of individuals at risk of having migraine (21,480), that was used as the denominator in calculating migraine prevalence, despite the limitations of using health insurance association data in Japan (please refer to Limitations section below) it is a valid method for investigating migraine prevalence, when it is not possible to use more traditional methods. Additionally as the response rate was relatively high, we believe that response bias is minimal.

On the basis of the survey results, including probable cases, the migraine prevalence was 3.2% (691/21,480). After weighting the data by sex and age among kencom users (Additional file 3) the prevalence of migraine was 3.5%. These migraine prevalence values were lower than the population prevalence of 8.4% reported by Sakai & Igarashi [3] in 1997. The relatively low value of migraine prevalence reported in this study’s survey results may partly be due to the fact that, whilst the questionnaires were structured, they were self-administered, and did not involve semi-structured interviews, which may have underestimated the migraine prevalence. The relative increase in migraine prevalence after weighting among kencom registrants may partially be explained by the fact that it is thought that kencom members have a higher level of health consciousness than the general Japanese population. There were, however many similar findings between our study and Sakai & Igarashi [3] that indicate that whilst migraine knowledge and treatment have progressed since 1997, many patients do not seek migraine specific treatments. These findings indicate migraine treatment and behaviors have not significantly changed since 1997.
Figure 4 shows the prevalence of migraine stratified by age and sex, with the number of same age and sex category used as the denominator. Our results are similar to previous findings [3, 4] that show migraine prevalence is higher in women than men and is most prevalent among individuals aged 30–40 years. As the kencom database includes individuals of working age, the majority of people with migraine (89.8%) were aged 30–59 years.

In our study the prevalence of migraine in women was 4.4% times higher than that in men showing that the etiology of migraine is poorly understood. This prevalence ratio among men and women remains relatively unchanged, since 1997 as Sakai & Igarashi [3] reported

| Variables | Migrainea (N = 691) |
|-----------|---------------------|
| Frequency of medical visits (past 6 months) | > Once/week 2 0.3<br>Once/2 weeks 0 0.0<br>Once/month 22 3.2<br>Once/2 months 10 1.4<br>Once/3 months 5 0.7<br><Once/3 months 5 0.7 |
| Reasons for initially seeing a doctor for headacheb (multiple answers) | Unable to tolerate headaches 106 15.3<br>Worried about other brain diseases 65 9.4<br>Increased headache frequency 55 8.0<br>OTC analgesics no longer effective 48 6.9 |
| Reasons for seeing a doctor once for headache and not seeing thereafterb (multiple answers) | Relieved not to have a brain disease that threatened life 18 2.6 |
| Reasons of not seeing a doctor in the past 3 yearsb (multiple answers) | OTC analgesics effective 260 37.6<br>Used to having a headache 155 22.4<br>Spontaneously resolving after endurance 143 20.7<br>Pain not sufficiently severe 114 16.5 |

Abbreviations: OTC Over-the-counter

a Migraine included individuals classified as probable migraine

b Details are listed in Additional File 1
**Table 4** Symptoms and triggers of migraine

| Variables                                      | Migraine<sup>a</sup> <br> (N=691) |
|-----------------------------------------------|------------------------------------|
|                                               | n | %     |
| Symptoms associated with headache<sup>b</sup> (multiple answers) |     |       |
| Nausea or vomiting                            | 345 | 49.9  |
| Stiff shoulder                                | 248 | 35.9  |
| Neck pain                                     | 185 | 26.8  |
| Site of pain (multiple answers)               |     |       |
| Unilateral                                    | 585 | 84.7  |
| Bilateral                                     | 198 | 28.7  |
| Frontal                                       | 181 | 26.2  |
| Occipital                                     | 178 | 25.8  |
| Periorbital                                    | 249 | 36.0  |
| Other                                         | 17  | 2.5   |
| Time of day (single answer)                   |     |       |
| Upon waking                                   | 195 | 28.2  |
| Morning                                       | 143 | 20.7  |
| Afternoon                                     | 302 | 43.7  |
| Evening                                       | 142 | 20.5  |
| Other                                         | 13  | 1.9   |
| No particular time                            | 223 | 32.3  |
| Headache triggers<sup>b</sup> (multiple answers) |     |       |
| Fatigue                                       | 327 | 47.3  |
| Mental or physical stress                    | 307 | 44.4  |
| Severe weather systems, such as typhoons      | 286 | 41.4  |
| Lack of sleep                                 | 261 | 37.8  |
| Turning points of the seasons                 | 208 | 30.1  |
| Sunny or rainy days                           | 191 | 27.6  |
| Work or housework                             | 178 | 25.8  |
| Menstruation<sup>c</sup>                      | 175 | 25.3  |

<sup>a</sup> Migraine included individuals classified as probable migraine  
<sup>b</sup> Details are in Additional file 3  
<sup>c</sup> Among those who had menstruation (325 patients), 171 patients (52.6%) answered “menstruation”

**Table 5** Activities refrained from to reduce the frequency of headaches in people with migraine (stratified by sex)

| Variables                                           | Migraine<sup>a</sup> <br>(N=691) | Male <br>(N=272) | Female <br>(N=419) |
|-----------------------------------------------------|-----------------------------------|-------------------|---------------------|
|                                                     | n | %     | n | %     | n | %     |
| Activities refrained from or reduced by headache   |     |       |    |       |    |       |
| Operating a computer or smart phone                 | 236 | 34.2  | 89 | 32.7  | 147 | 35.1  |
| Drinking alcohol                                   | 124 | 18.7  | 88 | 32.4  | 126 | 30.1  |
| Exercising such as playing sports or walking        | 129 | 18.7  | 58 | 21.3  | 71  | 16.9  |
| Going to crowded places                            | 215 | 31.1  | 58 | 21.3  | 157 | 37.5  |
| Driving a car                                      | 92  | 13.3  | 45 | 16.5  | 47  | 11.2  |
| Housework (excluding grocery shopping, laundry, and cooking) | 122 | 17.7  | 31 | 11.4  | 91  | 21.7  |
| Socializing with friends and playing with children | 83  | 12.0  | 25 | 9.2   | 58  | 13.8  |
| Going to grocery shopping                          | 108 | 15.6  | 18 | 6.6   | 90  | 21.5  |
| Taking public transportation                       | 65  | 9.4   | 14 | 5.1   | 51  | 12.2  |
| Cooking                                             | 104 | 15.1  | 11 | 4.0   | 93  | 22.2  |

<sup>a</sup> Migraine included individuals classified as probable migraine
that the prevalence of migraine in women was 3.6 times higher than that in men.

A high percentage of people with migraine (81%) did not attend a medical institute to consult with a doctor. Consequently, as in previous studies, it is thought that the percentage of undiagnosed cases was high [3, 4]. It was also shown that people with migraine usually attempt to ameliorate pain symptoms by taking only OTC drugs (57.8%) and do not see a physician until pain becomes unbearably severe. It was also clarified that even if patients do see a physician, they will often discontinue medical institution visits if the diagnosis confirms that they don’t have a life threatening brain disease.

Regarding migraine onset, it appears there is a sex difference regarding when headaches are likely to occur. Overall, regardless of sex, the most common reason was when feeling fatigue. Additionally, there is an increased tendency for migraine onset in the following

### Table 6  Headache medications in migraine

| Variables | Migraine\(^a\) (N = 691) |
|-----------|--------------------------|
|           | n | % |
| Medication use\(^b\) (past 6 months) | OTC and prescription drugs\(^c\) | 199 | 31.8 |
|           | Prescription drugs only (acute and prophylactic)\(^d\) | 38 | 6.1 |
|           | OTC drugs only | 362 | 57.8 |
|           | No prescription drugs\(^e\) | 27 | 4.3 |
| Number of OTC analgesic types | 1 | 403 | 58.3 |
|           | 2 or more | 158 | 22.9 |
| Types of prescription drugs\(^f\) (prophylactic, past 6 months) | Total | 56 | 8.1 |
|           | Antidepressants | 23 | 3.3 |
|           | Anti-epileptics | 13 | 1.9 |
|           | Calcium channel blockers | 11 | 1.6 |
|           | ARB/ACE inhibitors | 6 | 0.9 |
|           | Beta-blocker | 4 | 0.6 |
|           | Others | 6 | 0.9 |
| Types of prescription drugs\(^f\) (acute, past 6 months) | Total | 241 | 34.9 |
|           | Acetaminophen/NSAIDs | 206 | 29.8 |
|           | Triptans | 41 | 5.9 |
|           | Antiemetics | 28 | 4.1 |
|           | Intravenous steroids | 14 | 2.0 |
|           | Tranquilizer/anesthetic preparations | 6 | 0.9 |
|           | Tramadol | 1 | 0.1 |
|           | Magnesium preparations | 1 | 0.1 |
|           | Ergotamine | 0 | 0.0 |
|           | Hypertension | 51 | 7.4 |
|           | Cardiovascular disorders | 23 | 3.3 |
|           | Cerebrovascular disorders | 6 | 0.9 |
|           | Gastrointestinal disorders | 386 | 55.9 |
|           | Constipation | 50 | 7.2 |
|           | Psychiatric/Psychosomatic disorders | 104 | 15.1 |
|           | Depression | 48 | 6.9 |
|           | Epilepsy | 6 | 0.9 |
|           | Asthma | 51 | 7.4 |
|           | Allergy | 123 | 17.8 |
|           | Autoimmune disorders | 38 | 5.5 |

\(^a\) Migraine included individuals classified as probable migraine  
\(^b\) Denominator was the number who answered “yes” to a question of taking any drugs (n = 626)  
\(^c\) Data used from questionnaire responses and the medical claims database  
\(^d\) Data derived from the medical claims database  

### Abbreviations: OTC Over-the-counter, ARC Angiotensin II receptor blocker, ACE Angiotensin converting enzyme, NSAID Non-Steroidal Anti-Inflammatory Drugs
circumstances: when there are severe weather systems such as typhoons; at the turning point of seasons; and sunny or rainy days. Furthermore 52.6% of female respondents selected the reason of migraine onset to be related to menstruation, and amongst these individuals the majority endured the pain symptoms and attempted to ameliorate the pain by using OTC drugs.

Migraine symptoms were reported to cause individuals to refrain from or to reduce the conduct of everyday activities and essential household activities. Common activities included operating a computer or smartphone, drinking alcohol, and exercise such as playing sports or walking. Many women reported that they refrain from housework (excluding grocery shopping, laundry, and cooking) (21.7%) and grocery shopping (21.5%) due to headaches.

In assessing pain intensity, approximately 52.9% of respondents considered that the intensity of pain symptoms was severe. Moreover, the majority of patients (72.9%) considered that the impairment of daily life activities was of moderate or severe degree. This indicates that despite experiencing moderate/severe pain symptoms, the majority of patients continued with daily activities, rather than seeking medical attention or resting.

As stated above, in common with other studies [3, 4] the majority of patients used only OTC drugs (57.8%) to ameliorate pain. Only 6.1% of patients took only prescription medicines; and 31.8% of patients took both OTC and

### Table 7 Severity of impairment associated with medication use in migraine

| Migraine\(^{a}\) (N = 691) | Not taking medicines | Taking medicines |
|-----------------------------|----------------------|-----------------|
|                             | n  | %   | n   | %   |
| Severity of migraine\(^{b}\) |    |     |     |     |
| Severe                      | 365| 52.9| 47  | 6.8 |
| Moderate                    | 316| 45.7| 69  | 10.0|
| Mild                        | 10 | 1.4 | 510 | 73.8|
| Impairment in daily activities\(^{c}\) |    |     |     |     |
| Severe                      | 204| 29.5| 31  | 4.5 |
| Moderate                    | 300| 43.4| 56  | 8.1 |
| Mild                        | 187| 27.1| 539 | 78.0|

\(^{a}\) Migraine included individuals classified as probable migraine

\(^{b}\) Severity of migraine was grouped into 3 level from the patients’ response for evaluating the severity of a migraine attack in 5 levels: Severe: extreme or quite a bit of pain; Moderate: moderate pain; and Mild: little pain or no pain

\(^{c}\) Impairment in daily life was also grouped into 3 level from the patients’ response for evaluating the impairment in daily life when having a migraine in 5 levels: Severe: extreme difficulty or severe disruption in daily life; Moderate: moderate difficulty in daily life; and Mild: slightly interferes with daily life or no trouble at all

---

**Fig. 5** Domain scores of MSQv2.1 and WPAI in people with migraine (n = 691). Abbreviations: MSQ, Migraine-Specific Quality of Life Questionnaire; WPAI, Work Productivity and Activity Impairment Questionnaire; RR, role function—restrictive; RF, role function—preventive; EF, emotional function
prescription medicines. Acetaminophen and NSAIDs were prescribed to 29.8% of patients; and triptans to 5.9% of patients. Prescription drugs for prophylaxis were prescribed to 8.1% of patients. Whilst 59 patients were prescribed triptans for “other headaches”, as triptans are only used for migraine, it is highly likely that the “other headache” category includes migraine patients, as described below.

In our study a large number of “other headaches” was observed (24.2%). Among these "other headaches", 261 patients had two or more matches amongst three items for 1D-Migraine [18] and 286 patients had two or more matches for the 4-item-simple migraine screener developed in Japan [19]. These findings suggest that a doctor’s interview is important for the diagnosis of migraine. A correct migraine diagnosis, therefore, requires a detailed interview of symptoms with a doctor. This is not possible with self-administered questionnaires alone, and as it is difficult to select all patients, it is suggested that a combination of semi-structured interviews and questionnaires is useful for diagnosing migraine. Overall in our study it may be suggested that migraine headaches with symptoms of a degree of severity less than moderate were more likely to be unrecorded as migraines but as other headaches.

Limitations of the study
This study has limitations. Our findings are not generalizable to the entire adult population with headache in Japan due to the following reasons. Firstly, as we used data from employees and their family members of large companies that are members of the health insurance association contracted by DeSC and, therefore, this is not a population prevalence study. This limited generalizability is partly mitigated by the fact that the study population, included the family members of working individuals who may not be in the workforce. It should additionally be noted, however, that self-employed persons, civil servants, employees of small and medium-sized companies, and retired elderly persons are not included. It is assumed that employees of the companies in the DeSC database have a relatively high socioeconomic status, live in areas with access to medical care, and that their occupations are limited to certain types rather than being all encompassing. Secondly, the survey was distributed only to the kencom users. The users are considered to be more health-conscious than non-users and are more likely to take positive health actions in their daily lives, which may have affected QOL and WPAI scores. Thirdly, headache types were classified according to ICHD-3 based on an online survey. As medical consultations with doctors were not conducted it was, therefore, not possible to obtain detailed information regarding symptoms. Fourthly, a large portion of our data were self-reported, and questionnaire responses are subject to recall bias. Such bias is not present in certain variables (e.g., drug prescriptions and comorbidities); however, as we used an existing medical claims database that is used for billing purposes, such data are subject to misclassification and entry error. The above mentioned limitations may have led to errors in the classification of headaches, and may in part explain why the number of cases in the “other headache types” group was large. The results of this study should be interpreted with these potential biases in mind and the possibility that individuals in the “other headache types” group may have included individuals with migraine, tension type headache, etc.

A correct migraine diagnosis, therefore, requires a detailed interview of symptoms with a doctor. This is not possible with questionnaires alone, or a combination of semi-structured interviews and questionnaires.

Conclusion
Based on a unique method of linking medical claims and online survey data, we reported up-to-date epidemiological data of several headache disorders in Japan and showed that the current prevalence of migraine in Japan is approximately 3.2%.

In Japan, the percentage of people with migraine who did not receive medical attention is as high as 80%. Additionally, the majority of people with migraine tend to endure symptoms and continue with everyday activities. With innovative treatment approaches becoming available it is necessary to disseminate information that migraine requires specialized medical consultation and treatment. We consider that the findings of this study are of clinical value for future diagnosis and treatment of migraine headaches.

Abbreviations
OTC: Over-the-counter; NSAIDs: Non-steroidal anti-inflammatory drugs; CGRP: Calcitonin gene-related peptide; JMDC: Japan Medical Data Center; DeSC: DeSC Healthcare Inc.; CSS, Inc.: Clinical Study Support. Inc.; ICHD-3: International Classification of Headache Disorders, 3rd edition; HIA: Health Insurance Association; WPAI: Work Productivity and Activity Impairment; MS-QOL: Migraine-Specific Quality of Life; RR: Role function-restrictive; RP: Role function-preventive; EF: Emotional function; ARC: Angiotensin II receptor blocker; ACE: Angiotensin converting enzyme; MSQ: Migraine-Specific Quality of Life Questionnaire.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s10194-022-01439-3.

Additional file 1. Definition of migraine
Additional file 2. ICD-10 codes for headaches and comorbidities
Additional file 3. Sex and age distribution of each headache type and the prevalence of headache type after weighting by age and sex
Additional file 4. Characteristics of people with migraine (job category)
Additional file 5. Summary of reasons of seeing doctors in people with migraine (N=691)
Additional file 6. Symptoms and triggers of migraine (N=691)
Acknowledgements
This work was supported by Otsuka Pharmaceutical Co., Ltd. (Osaka, Japan). The statistical analysis was supported by Tatsuo Sakashita and Tetsumi Toyoda, Clinical Study Support Inc. (Nagoya, Japan) and medical writing was supported by Robert Phillips and Kyoko Inuzuka, Clinical Study Support Inc. (Nagoya, Japan) under contract with Otsuka Pharmaceutical Co., Ltd. (Osaka, Japan). Data management and extraction was supported by Akiko Tanaka from DeSC Healthcare Inc. (Tokyo, Japan).

Authors’ contributions
All authors made substantial contributions to all of the following: (1) the conception and design of the study, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be submitted and meeting the ICMJE authorship criteria. Additionally, HS, HK, YS and NK contributed to the acquisition of data. The author(s) read and approved the final manuscript.

Funding
This study was funded by Otsuka Pharmaceutical Co., Ltd.

Availability of data and materials
The data that support the findings of this study are available from DeSC Healthcare, Inc. (Tokyo, Japan) but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of DeSC Healthcare, Inc.

Declarations

Ethics approval and consent to participate
This survey used only anonymized data, and the ethical committee review was therefore not required, and no new individual level consent was obtained for the use of the data. However, the survey was conducted in consideration of the Declaration of Helsinki (revised October 2013) by the World Medical Association and the Ethical Guidelines for Medical Research Involving Human Subjects.

Consent for publication
Not applicable.

Competing interests
HS, HK, YS and NK are employees of Otsuka Pharmaceutical Co., Ltd. FS received consultant fee from Otsuka Pharmaceutical Co., Ltd., during the conduct of the study; consulting fees from Otsuka Pharmaceutical Co., Ltd., Eli-Lilly Co., and Amgen Co. Ltd.; lecture Honoraria from Otsuka Pharmaceutical Co., Ltd., Eli-Lilly Co., and Amgen Co. Ltd., outside the submitted work. KH received consulting fees from Otsuka Pharmaceutical Co., Ltd., during the conduct of the study; consulting fees from Otsuka Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Amgen Astellas BioPharma K.K., and Lundbeck Japan K.K.; lecture Honoraria from Otsuka Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Eisai Co., Pfizer Japan, Daiichi Sankyo Co., Ltd., MSD Co. Ltd., Amgen Astellas BioPharma K.K., and Lundbeck Japan K.K.; outside the submitted work. HI received consulting fees Otsuka Pharmaceutical Co., Ltd., during the conduct of the study; consulting fees from Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Eli Lilly Japan K.K., lecture Honoraria from Otsuka Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Amgen K.K., Daiichi Sankyo Co., Ltd., and Eisai Co., Ltd.; manuscript writing fee from Sawai Pharmaceutical Co., Ltd.; educational event fees from Lundbeck Japan K.K.; outside the submitted work. TT received consulting fees from Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and BioPharma K.K., during the conduct of the study; grants from Eisai Co., Ltd., Amgen Inc., Eli Lilly Japan K.K., and Allergan Japan K.K.; consulting fees from Otsuka Pharmaceutical Co., Ltd.; honoraria for lectures from Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Amgen Inc., and Eli Lilly Japan K.K., outside the submitted work. TN received consulting fees from Otsuka Pharmaceutical Co., Ltd., during the conduct of the study; consulting fees from Dai nippon Sumitomo Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd.; grants or contracts from JSR Co., Ltd., and Nakagawa Pharmacy Co.; lecture Honoria from Pfizer Japan Inc., MSD K.K., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Boehringer Ingelheim International GmbH, Eli Lilly Japan K.K., Baxter Ltd., Mitsubishi Tanabe Pharma Co., Otsuka Pharmaceutical Co., Ltd. and Novartis Pharma K.K., outside the submitted work.

Author details
1 Saitama International Headache Center, Saitama Neuropsychiatric Institute, 6-1-11 Honmachi-Higashi, Chuo-ku, Saitama 338-8577, Japan. 2 Department of Neurology, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsuga, Tochigi 321-0293, Japan. 3 Department of Internal Medicine, Headache Care Unit, Fujitsu Clinic, 4-1-1 Kamihokinokanaka, Nakahara-ku, Kawasaki, Kanagawa 211-8588, Japan. 4 Headache Center, Department of Neurology, Tomigaya Hospital, 1-4-48 Minatomachi, Naniwa-ku, Osaka 556-0017, Japan. 5 Department of Health Informatics, Graduate School of Medicine and School of Public Health, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. 6 Medical Affairs, Otsuka Pharmaceutical Co., Ltd, 3-2-27 Otedori, Chuo-ku, Osaka 540-0021, Japan. 7 Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Shinagawa Grand Central Tower, 2-16-4, Konan, Minato-ku, Tokyo 108-8242, Japan. 8 Medical Affairs, Otsuka Pharmaceutical Co., Ltd., 463-10 Kagaiono, Kawauchi-cho, Tokushima 771-0192, Japan.

Received: 30 March 2022 Accepted: 13 June 2022 Published: 23 June 2022

References
1. Headache Clinical Practice Guideline Development Committee (2021) Clinical practice guideline for headache disorders 2021. Japanese Society of Neurology, Japanese Headache Society, and Japanese Society of Neurological Therapeutics (eds). Igaku-Shoin, Tokyo. p 23 and p 143
2. GBD (2015) Neurological Disorders Collaborator Group (2017) Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neuro 16(1):877–897. https://doi.org/10.1016/s1474-4422(17)30299-5
3. Sakai F, Igarashi H (1997) Prevalence of migraine in Japan: a nationwide survey. Cephalalgia 17(1):15–22. https://doi.org/10.1046/j.1468-2982.1997.1701015.x
4. Takeshima T, Ishizaki K, Fukushima Y, Iiri T, Kusumi M, Wakutani Y et al (2004) Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache 44(1):18–19. https://doi.org/10.1111/j.1526-4610.2004.04004.x
5. Ando N, Fujimoto S, Ishikawa T, Teramoto J, Kobayashi S, Hattori A et al (2007) Prevalence and features of migraine in Japanese junior high school students aged 12–15 yr. Brain Dev 29(8):482–485. https://doi.org/10.1016/j.braindev.2007.01.003
6. Goto M, Yokoyama K, Nozaki Y, Itoh K, Kawamoto R, Matsumoto S et al (2017) Characteristics of headache in Japanese elementary and junior high school students: A school-based questionnaire survey. Brain Dev 39(9):791–798. https://doi.org/10.1016/j.braindev.2017.05.010
7. Ueda K, Ye W, Lombard L, Kuga A, Kim Y, Cotton S et al (2019) Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain 20(1):68. https://doi.org/10.1186/s10194-019-1012-1
8. Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F (2019) Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia 39(12):1518–1534. https://doi.org/10.1177/0333102419851855
9. Kikus, S, Chen Y, Todaka H, Asao K, Adachi K, Takeshima T (2020) Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey. J Headache Pain 21(11):110. https://doi.org/10.1186/s10194-020-01180-9
10. Igarashi H, Ueda K, Jung S, Cai Z, Chen Y, Nakamura T (2020) Social burden of people with the migraine diagnosis in Japan: evidence from a population-based cross-sectional survey. BMJ Open 10(11):e038987. https://doi.org/10.1136/bmjopen-2020-038987
11. Shimizu T, Sakai F, Miyake H, Sone T, Sato M, Tanabe S et al (2021) Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain 22(1):29. https://doi.org/10.1186/s10194-021-01243-5
12. Kotani K, Shimomura T, Ikawa S, Sakane N, Ishimaru Y, Adachi S (2004) Japanese with headache: suffering in silence. Headache 44(1):108–109. https://doi.org/10.1111/j.1526-4610.2004.t01-4-04020.x
13. Headache classification committee of the International Headache Society (IHS) (2018) The International classification of headache disorders, 3rd edition. Cephalalgia 38(1):1–211. https://doi.org/10.1177/0333102417738202
14. Rendas-Baum R, Bloudek LM, Maglinte GA, Varon SF (2013) The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients. Qual Life Res 22(5):1123–1133. https://doi.org/10.1007/s11136-012-0230-7
15. Speck RM, Shalhoub H, Ayer DW, Ford JH, Wyrwich KW, Bush EN (2019) Content validity of the Migraine-Specific Quality of Life Questionnaire version 2.1 electronic patient-reported outcome. J Patient Rep Outcomes 3(1):39. https://doi.org/10.1186/s41687-019-0138-x
16. Martin BC, Pathak DS, Sharfman MJ, Adelman JU, Taylor F, Kwong WJ, Jhingran P (2000) Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache 40(3):204–15. https://doi.org/10.1046/j.1526-4610.2000.00030.x
17. Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharma-coeconomics 4(5):353–365. https://doi.org/10.2165/00019053-199304050-00006
18. Lipton RB, Dodick D, Sadosky R, Kolodner K, Endicott J, Hettiarachchi J, Harrison W (2003) A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology 61(3):375–382. https://doi.org/10.1212/01.wnl.0000078940.53438.83
19. Takeshima T, Sakai F, Suzuki N, Shimizu T, Igarashi H, Araki N et al (2015) A simple migraine screening instrument: validation study in Japan. Japanese Journal of Headache 42(1):134–144

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.